Chronic HCV Infection and CKD

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Treatment of Patients With Chronic HCV Infection and CKD

HCV and CKD: A Tale of 2 Patient Populations

Patients With CKD Who Acquire HCV infection

Patients With CKD Who Acquire HCV infection (cont)

Patients With Chronic HCV Infection Who Develop CKD

Renal Diseases Associated With Chronic HCV Infection

Renal Diseases Associated With Chronic HCV Infection (cont)

Patients With CKD and Chronic HCV Infection: Implications for Practice

Burden of Disease

Treatment of Patients With CKD and Chronic HCV Infection: First-Generation DAAs Provided Promise of Better Outcomes

Dose Adjustments of All-Oral HCV Therapies in Patients With CKD

RUBY-I: Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin

C-SURFER: Elbasvir/Grazoprevir

Veterans Affairs System Study: Elbasvir/Grazoprevir

EXPEDITION-4: Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With Chronic HCV Infection and CKD

CERTAIN-1 and CERTAIN-2: Glecaprevir/Pibrentasvir in Patients With Chronic HCV Infection and CKD

CERTAIN-1 and CERTAIN-2: Glecaprevir/Pibrentasvir in Patients With Chronic HCV Infection and CKD (cont)

Sofosbuvir Not Recommended for Patients With GFR <30 mL/min/1.73 m2

Ledipasvir/Sofosbuvir in Patients With Chronic HCV Infection and CKD

Treating Chronic HCV Infection in Patients With Mild to Moderate Renal Impairment With DAA Agents

Treating Chronic HCV Infection in Patients With eGFR <30 mL/min/1 Treating Chronic HCV Infection in Patients With eGFR <30 mL/min/1.73 m2

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)